Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034019 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
A Phase 3 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT02034019 is a Phase 3 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 247 participants.
The verdict
NCT02034019, a Phase 3 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Interventions
- DRUG Dexamethasone
- DRUG Punctum Plug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02034019
The ClinicalTrials.gov registry entry for NCT02034019 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT02034019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02034019 about?
NCT02034019 is a clinical study titled "Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery". To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
What is the current status of trial NCT02034019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2014-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02034019?
The interventions under investigation include: Dexamethasone (DRUG), Punctum Plug (DRUG).
Who is sponsoring clinical trial NCT02034019?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.